HH 100937
Alternative Names: HH-100937Latest Information Update: 22 Jun 2024
At a glance
- Originator HaiHe Biopharma
- Class Antineoplastics; Small molecules
- Mechanism of Action SOS1 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Cancer